LONGEVITY with Dr. Elisabeth Roider MD, PhD, MBA
Today I am speaking with Dr. Elisabeth Roider, an esteemed ophthalmologist, who shares her expertise in advanced eye care and the latest innovations in treating eye diseases. We discuss the impact of technological advancements in ophthalmology and her approach to patient-centered care. Dr. Roider also highlights the importance of early detection and personalized treatment plans in preserving and enhancing vision.
Dr. Elisabeth Roider is a prominent ophthalmologist known for her specialized knowledge in the diagnosis and treatment of various eye conditions, including degenerative eye diseases. She holds a medical degree and has contributed significantly to the field through her clinical practice and research. Dr. Roider is actively involved in developing and utilizing cutting-edge technologies to improve the accuracy and effectiveness of eye treatments. Her work often focuses on innovative surgical techniques and therapies that offer hope to patients with complex visual impairments. Beyond her clinical and technical expertise, Dr. Roider is dedicated to educating her patients and the wider community about eye health, emphasizing the critical role of regular eye exams and preventive care in maintaining lifelong vision. Through her commitment to excellence in ophthalmology, Dr. Roider enhances the lives of her patients by restoring and protecting one of the most vital senses.
Follow Her on Instagram: https://www.instagram.com/dr.elisabethroider/
Chapters
00:00 Introduction to Longevity and the Guest's Background
02:49 The Intersection of Medicine, Science, and Business in Longevity
05:57 The Importance of Mental Health and Community in Longevity
08:48 The Evolving Longevity Industry and Its Mainstream Acceptance
11:55 Economic Implications of Longevity and Preventative Medicine
14:50 Practical Approaches to Longevity: Diet, Exercise, and Supplements
17:59 The Role of GLP-1 Agonists and Other Medications in Longevity
20:48 Personal Longevity Practices and Testing
Transcript
[00:00:00.280] - KAYLA BARNES-LENTZ
Welcome to the Longevity Optimization podcast, where we discuss longevity, optimal health, nutrition, peak performance, cognitive excellence, and so much more.
[00:00:11.030] - KAYLA BARNES-LENTZ
All right, Dr. Reunhardt, it's such a pleasure to have you here with me today.
[00:00:14.950] - DR. ELISABETH ROIDER, MD, PhD, MBA
Thank you for having me. It's a pleasure.
[00:00:16.890] - KAYLA BARNES-LENTZ
I've been loving getting to know you. We just met at the conference yesterday, and it's been so fun talking about longevity with you.
[00:00:24.900] - DR. ELISABETH ROIDER, MD, PhD, MBA
I agree. It's a wonderful conference, and every year there are new people coming in, and so you were one of the new ones. I'm very excited meeting you.
[00:00:32.030] - KAYLA BARNES-LENTZ
I know. And we had a bonding moment yesterday because we both wore the wrong shoes to the hike, the Lump hike.
[00:00:38.410] - DR. ELISABETH ROIDER, MD, PhD, MBA
Indeed, we had these not insignificant high heels hiking along our way. So no, it was lovely.
[00:00:45.800] - KAYLA BARNES-LENTZ
Yes, absolutely. Yeah, and we picked the same desserts, and we had the same menu. So I just love it.
[00:00:51.770] - DR. ELISABETH ROIDER, MD, PhD, MBA
Here we're sitting together. I know.
[00:00:54.020] - KAYLA BARNES-LENTZ
Here we are. I love it. I love it. So obviously, we're going to be talking about longevity today. Talk a little bit about your work? Because you have an interesting background. You're a medical doctor and a scientist, and now you're working on investments in the space. Tell me a little bit about that.
[00:01:09.430] - DR. ELISABETH ROIDER, MD, PhD, MBA
When you tell stories from now on, it all seems to make sense. But there were also times in the life where it wasn't clear, and if it wasn't sure about this, it makes sense what I'm doing. So by training, I'm MD, a medical doctor originally from Munich in Germany. After graduating, I went into residency in dermatology because I thought it's a very broad topic from preventative medicine to oncology treatments, kids, adults. So I really like this very broad aspect. I always loved research. So I started my scientific career very early on, originally coming from cancer research, first sarcoma, then melanoma. And via this cancer research, I went to Harvard, where I did the majority of my research, post-doc, PhD later, basically really understanding the cell biology mechanisms of redox biology, different trigger events of cancer. And as you might know, cancer on the mechanistic biological side is very close to longevity because the definition of an immortal cell is a cancer cell. I was already very much in that field. Moved down to Switzerland in 2016, had a classic career as a physician scientist, seeing patients, having academic grants, students, teaching. And there, basically, I realized I want to really bring what I'm doing to the masses.
[00:02:23.760] - DR. ELISABETH ROIDER, MD, PhD, MBA
I had different patterns. I was intrigued by friends who were in BC, they had startups, and I'm like, That's so cool. I mean, it's not you like this one-to-one. It's very rewarding having a patient and helping this in the middle, getting better, but really to have bigger solutions that can help so many. I did an MBA when an academic does. Done it. I just love it. And why are that? Where I have I'm the founder of Maximon, what is a venture studio, company builder in the space of longevity. Basically, since then, I'm officially in the longevity space. I've been doing a lot of longevity things like primary, secondary prevention before, and research in the space of aging, of redox biology. But this term as a longevity, as you might know, it's also rather new. It's finding itself. Basically, since a bit more than two years, I'm now officially part of Maximon, where I'm a partner, the Chief Scientific and Medical Officer. Here, what What we're doing is looking at this in a very holistic way. In contrast to other VC firms, we do not only do biotech. Actually, it's almost excluding biotech. It's really about consumer health applications.
[00:03:26.570] - DR. ELISABETH ROIDER, MD, PhD, MBA
This can be a supplement company. This is, for example, a diagnostics platform company where it can combine where it was it, genetic/epigenetic tests, clinics, like the first more or less democratized longevity clinics in Switzerland, a female health company, senior co-living concepts. As you can see, very broad. With that, I always try to bridge between medicine, science, and business, basically really bringing out very tangible solutions to the people.
[00:03:53.520] - KAYLA BARNES-LENTZ
I'm so impressed. Just thank you to lay that out there. And that's so interesting. You know One thing before we dive into longevity as a whole, I don't know much about these senior living facilities, but if it's anything like what's in my mind about it, is it incorporating longevity and senior living? Okay, this is so needed because it's so sad. So many people have, I think on a slide earlier, 30 years, they're saying. I was hoping it was more like 10, poor years, but a long time in later life that you are feeling not well and you Unfortunately, sometimes you have to go into these facilities, but this one sounds amazing. Tell me about it.
[00:04:34.150] - DR. ELISABETH ROIDER, MD, PhD, MBA
Yeah. Basically, maybe let's take one step back and then go speak about the facility. So when I started, longevity was a bit a wide range between we will live forever to you take this one single pill and then you will be cured from everything, and then others who are saying, Oh, it's just about biological clocks. So really, it was not defined. And also then people were speaking about CRISPR and stem cell and Everything was mixed together. I was like, Well, we need to structure that in a specific way. So for a paper which will hopefully come out, but this is basically just a summarize of the work I and my team did over the last years to basically put this in a pyramid setting and to say, what is actually the basis of what we're talking about? Basically, then the model now we're becoming almost a bit theoretical is like we say, Okay, we start with the diagnostics. We need to understand what's happening on the mental health side, on the biological health side. From there on, we need to work on physical Physical health, so food, nutrition, physical health, and of course, mental health.
[00:05:34.940] - DR. ELISABETH ROIDER, MD, PhD, MBA
Here we come into this core living in a second. Then we speak about supplements, we speak about off-label use, and then we speak about biotechnology innovation. Basically, we have this in a bit of a stagger process that really it's clear if we just do one gene, yeah, maybe we do something, but if we do wrong on all the bottom, you will not really flip the coin. From this pretty broad and holistic view, also this thinking about what do we do with the seniors who are very sad and lonely often, how can we bring them together? So basically having a concept there that mental health is really provided, encouraged, prevented, and so on in living communities, not for really old people like that they're 80 plus and are disabled and need help. It's more for fit and active seniors to keep them in that status as long as possible.
[00:06:23.120] - KAYLA BARNES-LENTZ
We know that social isolation has been shown and feeling lonely has been equited to that of the risk of smoking, right?
[00:06:35.130] - DR. ELISABETH ROIDER, MD, PhD, MBA
Yeah. And that's often what we totally oversee, that this mental health, this social well-being, this being embedded into a community, it's extremely important. Funny data. I was stumbling over the data that people who are a member for church, I think in that time it was about the Catholic Church, they outperform almost every longevity supplement. I was like, Wow, that's impressive. So it's probably this belonging to a group, Having a purpose, having really something to live for that helps the people to move and to be engaged and then also to remain fit.
[00:07:07.750] - KAYLA BARNES-LENTZ
I agree.
[00:07:08.840] - KAYLA BARNES-LENTZ
Hi. We're taking a short break from the podcast to discuss a new community that I have launched. I want to preface this by saying that I will continue to post content on my social platforms and conduct interviews on this podcast that are both free and applicable to both sexes. But as a woman, I have unique insights and perspectives on female health. I recently launched my first ever paid offering, and this is a female-only health optimization and longevity community. If you are a male, you can skip this portion of the podcast or you can forward this information to a female that you think would be interested. I set out to create the most valuable longevity optimization community for women. I have spent over the last decade dedicating my life to human optimization and have dived deep into the female-specific optimization and protocols. This is a place I want you to learn everything you need to know about optimizing your health, longevity, and mindset. I made this a community only for women because I wanted us to be able to be open, which I didn't feel could be done in the comment section of my Instagram. I also love the idea of women sharing protocols of what's working best, and everybody within the community can offer valuable insights to each other and support.
[00:08:23.570] - KAYLA BARNES-LENTZ
Members get weekly and bi weekly Ask Me Any Things, exclusive content and protocols articles, videos, and a whole host of courses, and you'll receive up to date female longevity science. You'll also get community in connection with like-minded women, access to virtual and in-person events with me, and your membership will help support Female Human Studies in the Very Near Future. You can learn more about this membership on my website, kailabarns. Com.
[00:08:53.010] - KAYLA BARNES-LENTZ
I feel as if that might be a big part of why people in the blue zones also have such extended life, because it's It's interesting. I mean, I'm not sure what your take on alcohol is, but I have it very, very rarely, if ever. But everyone always cites the blue zones, right? When it's related to alcohol. And I'm like, okay, but you can't compare yourself to those in the blue zones because they're living in a totally different life. You can't abstract one small piece of it, which is drinking alcohol, and then apply it to your normal life when they're outside a lot and walking and then community. So when they are drinking, it seems as if they're having it with friends in community. Yeah?
[00:09:28.700] - DR. ELISABETH ROIDER, MD, PhD, MBA
I think in general, that's a bit the problem with the longevity field, or maybe in general, when you search for something, you want to find simple solutions, and then you pick out one and you do your correlation analysis and say, Okay, fine. Here we have that. And if you do that, everything will be good. The point is it's a super multifactorial model, this aging. You have these hallmarks of aging, these hallmarks of aging drive specific phenotypes, if it's sarcopenia, so not so strong muscles or bone problems or cognitive abilities and so on. Then If all of the summer's up, you have the aged phenotype. So that's just what you see. And so I think also that's because it's so multimodal with so many networks. As you say, you will over a big population. If you take out the alcohol, I'm sure it will benefit, no doubt about that. But if it's then embedded in another context, it can be interpreted totally different. That's why it's unfortunately complex.
[00:10:23.580] - KAYLA BARNES-LENTZ
It is quite complex. There's so much that we still don't even know about the body, right?
[00:10:28.720] - DR. ELISABETH ROIDER, MD, PhD, MBA
Yeah, but that keeps I jump. I'm really much. I won't be hiking, so we're here, I guess.
[00:10:36.760] - KAYLA BARNES-LENTZ
With all your degrees, I don't think you'll be hiking.
[00:10:39.880] - DR. ELISABETH ROIDER, MD, PhD, MBA
Actually, I would love to hike. Let's go.
[00:10:42.100] - KAYLA BARNES-LENTZ
I know. Let's do that. I love it. Well, speaking broadly about the longevity industry, it's been super exciting. The opening statement this morning was that it's becoming a lot more mainstream. What have you seen over the years?
[00:10:57.450] - DR. ELISABETH ROIDER, MD, PhD, MBA
I think that's really encouraging because it It's considered as a mega trend since a while, but there are also mega trends that disappear. You got to be sure that it really remains. But what I also see from my own experience over the last years is that it's huge in use. You know it yourself, right? You're a bit of a focus person there, but also in Europe, it's like I have big newspapers, there are reports on longevity. It's just a question how and what way will it come? Then the question, if you speak about how will it come, that's what I think it's very encouraging. At the beginning, it was really these uber-rich people who said, We will live longer, forever, whatever. But this was a big marketing gig. But what I really see, I mean, that's hard data. We also had a talk about that today, is the population pyramid that we just have a huge fraction of people over 65. This is a huge problem for pensions, for health care systems, and so on. The moment I'm speaking with the four biggest health care insurance providers of Switzerland who are interested in the programs like the diagnostic program we are offering and the clinical application of what it really means for them.
[00:12:02.600] - DR. ELISABETH ROIDER, MD, PhD, MBA
I think this says or tells us that longevity will come by the masses now because it will not be that everybody's running a 2 million program of different longevity interventions. But for example, Why can be wrong, but gut feeling is that whatever sugar, for example, will be taxed as smoking or alcohol will be, so that that's taken away. You have incentives from health care providers that if you move more, if you do this and that, if you do these preventative classes, that you whatever get done, some deduction a bit in that way, that there are disciplines that's actually coming to the next point. What we see is that academic institutions are taking up the topic. I mean, at the moment, longevity, and that's actually very important to know for the people who listen now, longevity is not a medical discipline like hematology, dermatology, or surgery. It's something that's in the air, and people from all disciplines cover it. But there's no standardized curriculum. There's no society of... I mean, there's a society of longevity medicine, but there's not a board certification for whatever longevity medicine. I think this is coming slowly. The Health and Longevity Medicine Society has been starting on that.
[00:13:07.210] - DR. ELISABETH ROIDER, MD, PhD, MBA
Protocols are being developed, but this takes time. I think with all of this together, I really see this now becoming much more robust. The good thing is once it's just much more robust, it allow also investors to have more security in what they're investing in because that's what everybody's afraid of, that it's just discovered as a huge fluff. Then, of course, you lose quite some money. I think with more standardization, more investments will follow. Then with that also, it will even go quicker, the implementation into the daily routine.
[00:13:38.810] - KAYLA BARNES-LENTZ
Yeah, that's a really great point. I had asked a question yesterday when I was doing this filming for the Swiss television program. I let them know it was not my area of expertise, but they asked me what economic impact did I think that people, if we are able to live longer, what economic impact would that have? I'm What do you think?
[00:14:00.870] - DR. ELISABETH ROIDER, MD, PhD, MBA
I think that's actually a very important question. I even did a scientific study on that. There's one or two other scientific studies on that as well. Basically, it goes in a field of health economics. In short, I think you need to distinguish between living longer or living healthy longer or living healthier in general. So living longer itself without health will obviously cause costs. I think that's out of discussion. But if we speak about what is the amount of money we save by doing primary preventative medicine, that's very hard. So what I did, I'm happy to send you the paper later, where I used during COVID, we were not able to do preventative measurement medicine. So like for, as I'm a dermatologist, we're doing skin cancer screening. So for an average in Europe, we were in three months, we're not allowed to do skin cancer screening. So what this means, everybody's discovered three months later. So if you're in whatever, melanoma stage one, you move to stage two, it's stage three, or if you're not discovered, it will be discovered accordingly later. Basically, we calculated the number of people that move up in their stage, and every stage, the more advanced it is, the more cost it has.
[00:15:10.340] - DR. ELISABETH ROIDER, MD, PhD, MBA
Basically, we came up with an economic number of how many people this is, and this can be calculated in direct treatment cost, like how much is this cancer actually if you treat it? And more important, the indirect cost. If you were, I don't work, that's about 20 times more the cost than what actually the treatment of our cancer is. That's I think a big problem that people in the health economic system do not take so seriously. They often speak about the direct treatment cost. Instead, this loss of workability, which can last for a very long time, and is the real cost driver for economies. If you take that into account, we saw that the number was incredibly high, almost approaching actually the cost, what we have during COVID treatment for the whole topic itself. So very, very big numbers. There are proxies for chronic diseases, some others, which are present. And I think that's really the calculations that the health insurance providers and also the governments have to take. And once that's clear, I think it's a no-brainer that that will come.
[00:16:09.820] - KAYLA BARNES-LENTZ
I love that. It feels like the health insurance companies, though, are a bit behind.
[00:16:13.910] - DR. ELISABETH ROIDER, MD, PhD, MBA
Yeah, it depends a bit how they're incentivized. Switzerland has a different system than Germany, and that's again different from the US. Usually, they're very tightly connected to the governments, and so that also makes them not so agile. I think in the private health care, they should have a governmental part in the private part. In the private part, from my experience, they're pretty fast and want to move. They see, understand the value on the part that needs to be negotiated with the government. That just takes time. I don't know, long. One, two, three years, maybe even longer.
[00:16:50.540] - KAYLA BARNES-LENTZ
Yeah. Well, that's a great point, too, because I'm not aware, super familiar with the system here. But in the US, we know currently quite so a sick care system, I would say.
[00:17:01.050] - DR. ELISABETH ROIDER, MD, PhD, MBA
Yeah, because that's also where it's coming from, right? I mean, if we think about, I'm not sure if the number is correct, I heard it once. So if we speak of retirement age, 65, when that was introduced 100 years ago, about 3% of the population were above 65. Soon we have Half of the population being over 65. It's also like we have this huge shift where simply the regulations did not follow the actually the demographics. I mean, we can foresee what will happen, but still people only would... I think people want to feel it until they really change something. And I have to step back why this primary prevention is not so acute to follow on that. So if you have the majority of people under 65, they're not so suffering from these chronic diseases. Yes, of course you haven't, but at a very different frequency. So it was simply not as prevalent as it is today. And so with that shift, now with this extension in longevity, what we achieved, I mean, lifespan dramatically increased over the last 100 years, but the health span did not follow that. And so that's where we have this big bulk of chronic diseases sitting.
[00:18:05.910] - DR. ELISABETH ROIDER, MD, PhD, MBA
Yeah, because the direct treatments, like treating any fractures or infectious diseases, all of this was done very well. But the chronic diseases, they remained.
[00:18:16.020] - KAYLA BARNES-LENTZ
Yeah. I mean, in the US, chronic disease is just skyrocketing, unfortunately. I think it's like 70% or something of the population has at least one chronic disease, adult population. And that's now starting to trickle down to children, which is very concerning.
[00:18:33.640] - DR. ELISABETH ROIDER, MD, PhD, MBA
I see quite some changes happening in the obesity field. As you might know, it's a children's monogenous, which I think are very interesting, not only because they treat obesity or help to prevent further obesity, but also from a longevity side, but we can talk about that later. But I think if we're able to manage this obesity pandemic, a lot of the chronic diseases will go away or will be really reduced quite heavily because of arthritis, dementia, cardiovascular cardiovascular problems, all of this is very tightly bound.
[00:19:03.510] - KAYLA BARNES-LENTZ
Yeah. While we're on the topic of GLP-1s, we've been seeing in the news a lot of other potential benefits. Do you see any of those clinically or what are your thoughts?
[00:19:13.630] - DR. ELISABETH ROIDER, MD, PhD, MBA
Yeah. We don't have hard data on it yet. I mean, one side is as what I mentioned before, GLP-1 agonists, if you're waiting for weight reduction, if you're somewhat obese, I think there's no doubt that all the chronic diseases that follow that will also be better. The other side is like GLP-1s as treatments in the longevity space. If we speak about Ropamycin, metformin, I think also GLP-1 agonists should be added. Here, if you look at the pathways, they're very similar to what we're talking in the whole metabolic route. In my opinion, it makes total sense that this does play a role on the longevity space and on the longevity problems. Here also, we see that was the endpoints they're looking at. I The majority of that are age-related disorders. So I'm very curious to see what's happening, but I think over the next 20 years, it will be very interesting. I think there's even one trial on ovary age and she'll put one agonistif I remember correctly. I need to double check, but I'm pretty sure. I think there are like 30 plus trials running.
[00:20:19.840] - KAYLA BARNES-LENTZ
Yeah, I think I saw that, too. I think there's a few interesting ovarian aging studies ongoing right now, which is exciting, right? We know that women are waiting longer to have children, and I'm just excited to see what happens with that. Can you talk a little bit about, I suppose, the mechanism? So you're saying the GLP-1s, let's say you're not obese and you just wanted to do maybe like microdosing or something. We, of course, not talking about dosages, but what is happening there with the GLP-1 agnes?
[00:20:48.840] - DR. ELISABETH ROIDER, MD, PhD, MBA
Yeah, I mean, as I said, with the dosing, I do not want to go out of that route. In general, the dose makes the drugs and also the side effect profile. I think the lower you do something, the better your risk-benefit profile will be with a specific cutoff at some point. I think it's hard to nail it down to single pathway nodes, but in a nutshell, it's a bit similar to what's happening with metformin when you have this starvation signaling suddenly starting, where then have these regenerative processes being started. I do not want to go so far that I really say, Okay, this pathway, that pathway might be the trigger ones. But if you do an overlay of the different pathways, then basically it seems to be quite heavily involved in many angles.
[00:21:38.910] - KAYLA BARNES-LENTZ
Well, that's so exciting. I mean, it's a peptide, right? We have done peptides. Well, we did before the FDA decided to pull them. But we saw a lot of really great benefits with a lot of different peptides from PPC and recovery, regeneration, and CJC helping people put on a little bit of muscle mass. There's a little bit of body fat. So I'm excited. Well, I'm interested to see what happens with that. So now they're not in compounding pharmacies. I'm excited to see if we bring them mainstream or what. But I think there's some pretty powerful exogenous molecules out there that can benefit longevity, bone, muscle, all the things that we know cause aging.
[00:22:21.120] - DR. ELISABETH ROIDER, MD, PhD, MBA
I agree.
[00:22:22.540] - KAYLA BARNES-LENTZ
All right, so let's talk about some practical... Now we're going to tap into your medical doctor side. Let's talk about some practical things. What are you doing to improve your longevity?
[00:22:35.120] - DR. ELISABETH ROIDER, MD, PhD, MBA
In general, I'm a bit reluctant to say, Oh, do this, this, and this, and then you will live forever or as long as possible. One of the reasons is that as a doctor, I feel that I have special responsibility to make sure that the clinical trials are in place to back that. But maybe to speak in very simple terms and a bit more generalistic so people can orientate on it and then from there and they can see their Specific, if it's a general doctor or a longevity doctor, I think it's important that they have someone who they trust with this topic. I mean, in general, classics are food and exercise. I mean, food, I think we have a bit of an overload of carb, or in some areas, a quite significant overload of carbs, which is very close to the shores, right? Rice, pasta, potatoes, and all of this. I'm not saying take it out completely, like the hard keto diet, but a bit on the more lean I think that's something what a majority can benefit of on the exercise. Here also, we have quite good guidelines in place, but I think if people try to exercise maybe three times per week with a mix of endurance, and especially muscle mass.
[00:23:45.750] - DR. ELISABETH ROIDER, MD, PhD, MBA
I think that's something that's really important because muscle mass is so important also for your longevity, for your aging. Also, then if we speak about the medical intervention, that like GLP-1s, I think here that's actually important to come in. Supplements, for sure, personalized. Here we have a huge variety. Unfortunately, it's often not personalized, often because the guidelines are unclear, the ranges are not clear.
[00:24:10.820] - KAYLA BARNES-LENTZ
Sometimes the ranges aren't even what's in the bottle.
[00:24:14.240] - DR. ELISABETH ROIDER, MD, PhD, MBA
You can obviously get third-party lamb testing, all the things. I think that's the tough. We have one company of Avia. I think they have nice bundles in place. But even then, I think it's always good to check. There are quite a few supplements that are back a bit better. Now we have from this year, for example, spermedin, which seems, especially if you combine it with exercise, to be very efficient. Let's see. There's more and more coming out. As you know, the supplement market is as unregulated as the cosmetic market because it's supposed to do no harm. I'm a bit reluctant with that. I think if you do really too many, you can do harm. Also, you can overdose that, so be a bit careful. I can recommend that you follow the AMAIA company we have. There are other very good supplement companies as well, but have something, don't overdo it. What do you think is overdoing it?
[00:25:01.190] - KAYLA BARNES-LENTZ
Like 10 pills, 20?
[00:25:03.270] - DR. ELISABETH ROIDER, MD, PhD, MBA
If you really have an issue, then it can be more. But I think once you exceed the 10 pills, it's getting a bit tricky, but this is a number I throw in the room arbitrary. I know you take more. You have vitamin D and you have iron just as the baseline. Something I actually would like to explicitly also discuss is this NID pathway, the Metabolism pathway. It's very much hight in the media because there are also influencers talking about it. I think here also, if you are prone to cancer, be aware of whatever you're doing in the longevity space, no matter if you're speaking of off-level drugs or supplements, really double-check because everything you're doing is giving energy to your body. If you have anything, you had a cancer, you're prone to cancer, really be careful and double-check that. Maybe do not do the super high potent things, just as a sign note.
[00:25:57.760] - KAYLA BARNES-LENTZ
No, that's great.
[00:25:59.440] - DR. ELISABETH ROIDER, MD, PhD, MBA
Then if we speak about drugs, I think off-label drugs, here, in my opinion, it's a mix out of anti-inflammatory agents. I mean, rapamycin is here a very classic one, and Averalodos for sure, but again, it's off-label. Aspirin has also good benefits for multiple reasons, not only on the inflammatory side, obviously, also on the blood clotting other prevention side with P4. Then you have this metabolic arm. I think so far there was metformin. Now we have the GLP-1 agonists that are coming in. Here, I think it needs to also be a bit tailored to gender, age, but especially age. I think here it plays a role. For example, my feeling is metformin is a bit better for the elderly PEM-population. Maybe the GLP-1 is a bit for the younger, a bit more of these ones. I think here, here's some medical lead needed, but any way you need it because it's prescriptive drugs. Then other things is this hormesis concept that you have small stressors in your life, like heat, cold, obviously. If even you don't have a cryo, you can shower cold, you can go to the sauna, like all these things. And the conscious therapy, like oxygen stress signals.
[00:27:15.320] - DR. ELISABETH ROIDER, MD, PhD, MBA
I'm sure you spoke about that so much already. Ihet, hyperbaric oxygen. In the end, it's always like giving a little push to your body, then taking it away and give some time to recover. I think this is a bit the bread and butter longevity routine that I would say most can benefit of. But again, I think I really hope that now with the emerging market of the longevity clinics, that there's a bit more guidance. I was just talking to two other doctors who also have clinics in London. We exchanged the protocols. We're like, Okay, finally. It seems like we're doing more or less the same thing. But you see, that's still where we are. Different doctors do different things. It's not so much standardized. My guess is in the next five years, we will have much clearer guidelines of what to do.
[00:28:01.820] - KAYLA BARNES-LENTZ
And of that, what are some of your favorite labs to run and what are you looking for?Labs.
[00:28:06.970] - DR. ELISABETH ROIDER, MD, PhD, MBA
You mean like a bloodwork laboratory?Bloodwork.
[00:28:08.610] - KAYLA BARNES-LENTZ
Or toxin testing, gut health testing? What are some of your favorites?
[00:28:13.600] - DR. ELISABETH ROIDER, MD, PhD, MBA
Well, medically, the most established is vitamin D. I mean, that's very obvious. Then consumer-wise-Or even for yourself.
[00:28:24.370] - KAYLA BARNES-LENTZ
What are you testing on yourself?
[00:28:27.210] - DR. ELISABETH ROIDER, MD, PhD, MBA
Well, iron vitamin D, I think that's really the baseline. We have not that boring. I don't know. We have with Ayun a pretty comprehensive panel in place. We're happy to also introduce you as the lady, to go in all of these details. Yeah, we have it there. We're also doing our own measurements test to see how well is that reflecting then also the offerings we have. If we have IHT, HBO, and so on, how much is it really reversed? This is also I think what is really the therapeutic consequence of the bloodworks we do. And that's actually, by the way, that's also why I'm a bit reluctant discussing that further, is that the longevity field is criticized heavily from the classic medicine field for overdiagnosing and for doing things, just to be active, testing things without knowing what the real consequence is. Here, I think that's something where we need to be a bit careful. What I still think is also, here we're also coming in the gray field, but If we were to speak about genetic risk profiling, APOE4, for example, like this dementia, I'm sure you discovered that. That's also something not to tell people, Oh, that's what's going to happen here.
[00:29:40.670] - DR. ELISABETH ROIDER, MD, PhD, MBA
It's not the case. But maybe you can change your lifestyle, your behavior in a specific way. I think this is something where everybody should go through and where everybody can benefit from. Then, of course, we have this big clock discussion. That's what I was just going to say about the consumer market. I think this is something that's interesting because it's an additional test asset that you can provide and hook where people come in. But here again, we know now that it's a proxy, but it's important to have then different insights, different clocks, and so on to really combine it.
[00:30:15.150] - KAYLA BARNES-LENTZ
Yeah, I agree with that. Well, I would go through all the tests I do, but not like, I'm left three hours. I'm sure you're doing everything.All the things. You better shoot. All the time. Well, this has been such a pleasure to chat with you.
[00:30:27.020] - DR. ELISABETH ROIDER, MD, PhD, MBA
Same.
[00:30:27.580] - KAYLA BARNES-LENTZ
Thank you so much for coming on.
[00:30:29.060] - DR. ELISABETH ROIDER, MD, PhD, MBA
What a lovely talk I you. I'm sure we'll continue.
[00:30:31.700] - KAYLA BARNES-LENTZ
I know. You have to come visit in LA soon.
[00:30:33.890] - Speaker 4
Will do. This podcast is for informational purposes only, and views expressed on this podcast are not medical advice. This podcast, including Kyla Barnes, does not accept responsibility for any possible adverse effects from the use of the information contained herein. Opinions of their guests are their own, and this podcast does not endorse or accept responsibility for statements made by guests. This podcast does not make any representations or warranties about guest qualifications or credibility. Individuals on this podcast may have a direct or indirect financial interest in products or services referred to herein. If you think you have a medical issue, consult a licensed physician.